Insulet (NASDAQ:PODD – Get Free Report) and NWT Uranium (OTCMKTS:CPTRF – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.
Profitability
This table compares Insulet and NWT Uranium’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Insulet | 9.12% | 24.90% | 10.73% |
| NWT Uranium | N/A | -157.37% | -147.81% |
Valuation and Earnings
This table compares Insulet and NWT Uranium”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Insulet | $2.71 billion | 4.85 | $247.10 million | $3.50 | 54.16 |
| NWT Uranium | $27.25 million | N/A | $6.69 million | $4.08 | 0.04 |
Insulet has higher revenue and earnings than NWT Uranium. NWT Uranium is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current recommendations and price targets for Insulet and NWT Uranium, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Insulet | 1 | 5 | 18 | 0 | 2.71 |
| NWT Uranium | 0 | 0 | 0 | 0 | 0.00 |
Insulet currently has a consensus price target of $327.24, indicating a potential upside of 72.63%. Given Insulet’s stronger consensus rating and higher probable upside, equities analysts plainly believe Insulet is more favorable than NWT Uranium.
Summary
Insulet beats NWT Uranium on 9 of the 10 factors compared between the two stocks.
About Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
About NWT Uranium
Captor Capital Corp. engages in the manufacture and retail sale of cannabis products in the United States. It operates two dispensaries under the CHAI Cannabis Co. brand in Santa Cruz and Monterey, California, as well as operates an e-commerce site under the CHAI-brand. The company was formerly known as NWT Uranium Corp. and changed its name to Captor Capital Corp. in June 2017. Captor Capital Corp. was incorporated in 2003 and is based in Toronto, Canada.
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
